paclitaxel has been researched along with Cancer of Skin in 193 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (5.70) | 18.2507 |
| 2000's | 65 (33.68) | 29.6817 |
| 2010's | 90 (46.63) | 24.3611 |
| 2020's | 27 (13.99) | 2.80 |
| Authors | Studies |
|---|---|
| Hiura, A; Maeda, T; Nakagawa, T; Toyoshima, R; Uehara, J; Yoshino, K | 1 |
| Kitamura, S; Seo, T; Ujiie, H; Yanagi, T | 1 |
| Adhav, R; An, T; Chan, UI; Deng, CX; Lei, JH; Li, J; Liu, J; Miao, K; Mo, L; Shu, X; Su, SM; Wang, Y; Xu, J; Xu, X; Zhang, X | 1 |
| Chen, T; Chen, X; Cheng, W; Jiang, Y; Nie, X; Zhong, Y | 1 |
| Bi, S; Cen, Y; Chen, J; Li, J; Yin, X; Zhong, A | 1 |
| Chawla, SP; Dewnani, K; Goldfarb, SB; Iacobucci, M; Lacouture, ME; Lang, JE; Markova, A | 1 |
| Lan, M; Li, AA; Li, F; Xie, D; Yan, MY; Zhang, Y | 1 |
| Bąk, W; Bargieł, J; Cabaj, J; Góralczyk, A; Grabarska, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Lan, S; Wu, D; Zhang, Y | 1 |
| Ahmed, MA; Aydiner, A; Doğan, İ; Ferhatoğlu, F; Karaman, S; Khanmammadov, N; Paksoy, N | 1 |
| Asano, Y; Fujimura, T; Fujisawa, Y; Hashimoto, A; Ishizuki, S; Ito, T; Kambayashi, Y; Kato, H; Maekawa, T; Matsushita, S; Segawa, K; Yamamoto, J; Yoshino, K | 1 |
| Choueiri, MA; Dietz, MD; Zelmanski, MH | 1 |
| Egawa, G; Endo, Y; Fujii, H; Ishikawa, M; Kabashima, K; Yonekura, S | 1 |
| Dülgar, Ö; Elleson, KM; Markowitz, J; Saha, A | 1 |
| Bagot, M; Baroudjian, B; Basset-Seguin, N; Chapalain, M; Dupont, A; Lambert, J; Lebbe, C; Lhote, R | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
| Anderson, DM; Erickson, LA; Ernstoff, M; Javed, A; Markovic, SN; Reid, JM; Suman, VJ; Wall, DJ | 1 |
| Boulinguez, S; Casassa, E; Chira, C; Gangloff, D; Lamant, L; Meyer, N; Montastruc, M; Paul, C; Riffaud, L; Sibaud, V | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Saito, Y; Umemori, Y; Yokoyama, R | 1 |
| André, F; Frischhut, N; Nguyen, VA; Schmuth, M; Skvortsov, S; Walder, A | 1 |
| Chen, S; Feng, R; Song, Z; Wen, Y; Xu, H; Zhu, L | 1 |
| Maeda, T; Nakano, E; Namikawa, K; Oashi, K; Shibata, T; Takahashi, A; Teramoto, Y; Tsutsumida, A; Yamazaki, N; Yokota, K | 1 |
| Gebhardt, C; Gries, M; Holland-Letz, T; Mun, DH; Reinhard, R; Simon, SCS; Umansky, V; Utikal, J; Weber, R | 1 |
| Chan, JCH; Chang, CC; Chen, TW; Endo, M; Farid, M; Goh, WL; Hirose, T; Kawai, A; Leung, AKC; Loong, HH; Maw, MM; Mingmalairak, S; Ngan, RKC; Pang, A; Puhaindran, ME; Quek, R; Sriuranpong, V; Tan, SH | 1 |
| Keam, B; Kim, DW; Kim, M; Kim, SH; Kim, TM; Kim, YJ; Kwak, Y; Moon, KC; Park, C | 1 |
| Lee, Y; Park, D | 1 |
| Berges, A; Cho, H; Dean, E; Hong, JY; Irurzun-Arana, I; Kang, WK; Kim, KM; Kim, ST; Kozarewa, I; Lee, J; Lim, HY; Loembé, AB; Mortimer, P; Park, JO; Park, SH; Park, YS; Pierce, AJ; Smith, C; Smith, SA; Willis, S | 1 |
| Dingv, Y; Huang, FX; Jiang, H; Li, DD; Li, JJ; Liu, X; Wang, JH; Wen, XZ; Zhang, XS; Zhao, JJ | 1 |
| Funakoshi, T; Hirai, I | 1 |
| Li, C; Li, Z; Luan, Y; Wu, J; Zhang, H; Zhao, D | 1 |
| Baniandrés Rodriguez, O; Ciudad Blanco, C; Ruedas Martínez, A; Vilas Boas, P | 1 |
| Chen, MB; Laber, DA | 1 |
| Bauer-Pohl, V; Bennett, K; Beqiri, M; Chen, G; Choi, H; Czerniecki, BJ; Damle, M; Davies, MA; Dunagin, M; Ellingsworth, C; Flaherty, K; Frederick, DT; Fukunaga-Kalabis, M; Garg, K; Gavin, BJ; Grinman, L; Griss, J; Gross, L; Hafner, C; Hards, R; Herlyn, D; Herlyn, M; Hristova, D; Hudgens, C; Jalili, A; Karanikas, G; Koller, J; Krepler, C; Lang, R; Liu, Q; Long, GV; Maurer, M; Mayerhöfer, M; Perego, M; Raj, A; Rappersberger, K; Schaider, H; Scholler, N; Schuchter, L; Scolyer, RA; Somasundaram, R; Tetzlaff, M; Tian, T; Wagner, C; Wagner, SN; Wargo, J; Watson, I; Wei, Z; Weihsengruber, F; Wu, L; Xu, X; Zhang, G; Zhang, J | 1 |
| Boisgerault, N; Coffey, M; Diaz, RM; Evgin, L; Harrington, K; Ilett, E; Kottke, T; Melcher, A; Pandha, H; Rommelfanger, D; Selby, P; Shim, KG; Thompson, J; Vile, R; Zaidi, S | 1 |
| Gao, X; Hu, X; Li, G; Song, Q; Tan, S; Wu, T; Yin, Y; Zhang, Z; Zhao, Y | 1 |
| Dabouz, F; Farhat, MM; Le Guern, A; Modiano, P; Peugniez, C; Quinchon, JF | 1 |
| Hong, JH; Khurelbaatar, T; Lee, JK; Lee, NW; Lee, S; Min, KJ; Ryu, KJ; Song, JY | 1 |
| Hamaguchi, Y; Kitano, T; Maeda, S; Matsumoto, I; Mizumaki, K; Oishi, K; Saito, D; Takehara, K; Yoshida, S | 1 |
| He, B; Jiang, T; Li, T; Ma, Y; Mo, R; Shen, S; Wang, T | 1 |
| Jung, YH; Lee, SH; Park, HJ; Yoo, JY | 1 |
| Armstrong, P; Gavino, AC; Reichenberg, JS; Woody, MM | 1 |
| Awazawa, R; Fukai, K; Kamo, R; Kusutani, N; Omura, R; Osawa, M; Ozawa, T; Tsuruta, D | 1 |
| Cun, X; He, Q; Li, M; Liu, Y; Tang, X; Wei, J; Xu, C; Yang, Y; Yin, S; Yu, Q; Zhang, Z | 1 |
| Chowdhury, MR; Goto, M; Kamiya, N; Moniruzzaman, M; Moshikur, RM; Tahara, Y; Wakabayashi, R | 1 |
| Chang, W; Choi, MK; Hong, JY; Jung, HA; Kim, S; Kim, YS; Lee, J; Lee, SJ; Maeng, CH; Park, S | 1 |
| Glass, LF; Jukic, DM; McNab, PM; Quigley, BC | 1 |
| Arrowsmith, ER; Hainsworth, JD; Hauke, RJ; Infante, JR; Rubin, MS; Shih, KC | 1 |
| Chin, F; Farid, M; Ho, ZC; Jeevan, R; Lee, MJ; Ong, WS; Poon, D; Quek, R; Sairi, AN; Soh, LT; Teh, J; Teo, M | 1 |
| García-Silva, J; Nespereira-Jato, MV; Peña-Panabad, C; Quindós-Varela, M | 1 |
| Argenyi, ZB; Choi, WT; George, E; Olerud, JE; Stetsenko, GY; Zhang, J | 1 |
| Ashida, A; Okuyama, R; Sato, Y; Uhara, H | 1 |
| Amaravadi, RK; Anderson, AR; Fedorenko, IV; Gibney, GT; Kim, E; Kudchadkar, RR; Maria-Engler, SS; Massaro, RR; Messina, JL; Rebecca, VW; Smalley, KS; Sondak, VK | 1 |
| Koon, HB; Megahed, AI | 1 |
| Arance, A; Conti, I; Garbe, C; Grob, JJ; Hahka-Kemppinen, M; Hamid, O; Hauschild, A; Hutson, TE; Ilaria, R; Kaiser, C; Lee, J; Lorigan, P; Maio, M; Mohr, P; Turner, PK; Wolter, P | 1 |
| Fallon, JK; Fu, Q; He, Z; Liu, D; Liu, F; Ma, Y; Wang, D; Wang, Y; Yang, X | 1 |
| D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F | 1 |
| Fujimoto, M; Fujisawa, Y; Kadono, T; Miyagawa, T; Nakamura, Y; Yoshino, K | 1 |
| Arima, H; Eguchi, Y; Hirata, M; Ijichi, T; Ishigami, S; Kijima, Y; Kurahara, H; Nakajo, A; Natsugoe, S; Okumura, H; Shinden, Y; Uenosono, Y; Yoshinaka, H | 1 |
| Hamburger, T; Nechushtan, H; Peretz, T; Salmon, AY; Stainberg, H; Vainer, G | 1 |
| Aoyagi, S; Hata, H; Homma, E; Shimizu, H; Tsujiwaki, M | 1 |
| Gota, V; Mehta, M; Patel, K; Patil, A; Vavia, P | 1 |
| Banerjee, R; Joshi, KS; Joshi, N; Shirsath, N; Singh, A | 1 |
| Ciria, C; Collins, L; Corrie, P; Coupe, N; Gore, M; Gupta, A; Hategan, M; Larkin, J; Love, S; Middleton, MR; Suter, S; Wise, A | 1 |
| Araki, T; Higaki, K; Kawai, R; Ogawara, K; Ono, T; Suzuki, H; Watanabe, T | 1 |
| Boasberg, P; Cruickshank, S; Hamid, O; Mesko, S; O'Day, S; Spitler, LE; Weber, RW | 1 |
| Aoi, J; Fukushima, S; Ihn, H; Jinnin, M; Kajihara, I; Kanemaru, H; Masuguchi, S; Miyake, T | 1 |
| Alfano, D; Caputo, E; Cavalcanti, E; Fico, A; Patriarca, EJ; Travali, S; Valentino, A; Vasta, V | 1 |
| Abhyankar, S; Chang, CL; Donga, P; Munakata, J; Reyes, CM; Schabert, VF; Yim, YM | 1 |
| Grothey, A; Phuoc, V | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, PA; Chevreau, C; Clisant, S; Collard, O; Cupissol, D; Delcambre, C; Domont, J; Isambert, N; Italiano, A; Le Cesne, A; Mir, O; Penel, N; Piperno-Neumann, S; Ray-Coquard, IL; Saada-Bouzid, E; Tresch-Bruneel, E | 1 |
| Ding, Y; Guo, YQ; Li, DD; Li, JJ; Peng, RQ; Wen, XZ; Zhang, X; Zhang, XS | 1 |
| Karam, A; Kong, CS; O'Keefe, MC; Westhoff, GL; Wheeler, L | 1 |
| Pathak, K; Sharma, M; Sharma, V | 1 |
| Carlino, MS; Long, GV | 1 |
| Amaya, CN; Bryan, BA; Chow, M; Chow, W; Dickerson, EB; Rains, S | 1 |
| Agarwala, SS; Bhatia, S; Brachmann, C; Brown, MP; Clawson, A; Conry, R; Del Vecchio, M; Elias, I; Ernst, S; Grob, JJ; Gutzmer, R; Hauschild, A; Haydon, A; Hersh, EM; Homsi, J; Karnoub, M; Kefford, R; Kendra, K; Li, M; Loquai, C; Renschler, MF; Robert, C; Testori, A | 1 |
| Leon-Ferre, RA; Markovic, SN | 1 |
| Ishitoya, S; Onishi, H; Takeuchi, E; Terashima, T; Uemura, Y; Ushida, H | 1 |
| Chen, Y; Cheng, K; Du, Y; Gou, HF; Li, C; Liu, JY; Wu, J; Xu, F; Yang, Y; Yuan, L | 1 |
| Bharadwaj, R; Das, PJ; Mazumder, B; Pal, P | 1 |
| Cheng, PF; Dummer, R; Goldinger, SM; Guenova, E; Jaberg-Bentele, N; Kunz, M; Levesque, MP; Mangana, J; Nagel, HW; Nägeli, M; Thurneysen, S; Ziegler, M | 1 |
| Blank, C; Cranmer, L; Daud, A; Dummer, R; Ebbinghaus, S; Hamid, O; Hauschild, A; Hille, D; Kang, SP; Loquai, C; Mehnert, JM; O'Day, S; Puzanov, I; Ribas, A; Robert, C; Salama, A; Schachter, J; Schadendorf, D; van den Eertwegh, A; Zhou, W | 1 |
| Bhadra, MP; Bhadra, U; Garikapati, KR; Reddy, BV; Reddy, SG; Reddy, TL; Yadav, JS | 1 |
| Huong, PT; Minh, NV; Thang, ND | 1 |
| Allison, KH; Childs, JS; Coveler, AL; Dang, Y; Disis, ML; Higgins, DM; Lu, H; Reichow, JL; Salazar, LG; Waisman, J | 1 |
| Amagai, M; Fujita, T; Fukuda, K; Funakoshi, T; Kawakami, Y; Mori, M; Nakamura, Y; Okamoto, M; Sakurai, T; Taguchi, J; Tanese, K; Tanikawa, A | 1 |
| Chopitea, A; Díaz-Lagares, A; Espinós, J; González, A; González-Cao, M; Martín-Algarra, S; Nieto, Y; Ponz, M; Redondo, P; Viteri, S | 1 |
| Blay, JY; Hartmann, JT; Hogendoorn, PC; Judson, I; Marreaud, S; Reichardt, P; Schlemmer, M; Thyss, A; Van Glabbeke, M; Verweij, J | 1 |
| Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A | 1 |
| Bay, JO; Blay, JY; Bompas, E; Brain, EG; Bui, BN; Chevreau, C; Cupissol, D; Fournier, C; Isambert, N; Jimenez, M; Kerbrat, P; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I; Taieb, S | 1 |
| Bachelot, T; Colin, C; Fournel, C; Ganne, C; Jacquin, JP; Jaisson-Hot, I; Lenoir, VT; Marechal, F; Mechin-Cretinon, I; Orfeuvre, H; Peaud, PY; Poncet, B; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Gagnon, PJ; Galderisi, C; Holland, JM; Page, BR | 1 |
| Amatruda, T; Constantinou, CL; Egner, JR; Fitch, TR; Jilani, SZ; Kottschade, LA; Markovic, SN; Morton, RF; Perez, DG; Suman, VJ | 1 |
| Amano, S; Enomoto, K; Kitajima, A; Sakurai, K; Shiono, M; Tani, M | 1 |
| Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C | 1 |
| Berneburg, M; Clasen, S; Eigentler, T; Forschner, A; Garbe, C; Guenova, E; Knaudt, B; Leiter, U; Meier, F; Zielinski, C | 1 |
| Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
| Alexandrescu, DT; Dasanu, CA; Ichim, TE; Kabigting, F | 1 |
| Bedikian, A; Gerber, DL; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Ring, S | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Mahoney, SL; Papadopoulos, NE | 1 |
| Abbas, O; Haddad, F; Kibbi, AG; Salem, Z | 1 |
| Hide, M; Hori, I; Kamegashira, A; Madokoro, N; Mihara, S; Noda, H; Shindo, H; Takahagi, S | 1 |
| Clawson, AA; Gonzalez, R; Gordon, MS; Hersh, EM; O'Day, SJ; Ribas, A; Samlowski, WE; Shechter, DE | 1 |
| Cozzio, A; Donghi, D; Dummer, R | 1 |
| Atkins, MB; Bhatt, RS; Heymach, JV; McDermott, D; Merchan, J; Parker, R; Seery, V; Sukhatme, VP; Wu, HK; Zhang, L | 1 |
| Gonlusen, G; Paydas, S; Yapar, Z | 1 |
| Borroni, G; Brazzelli, V; Ciocca, O; Fiandrino, G; Rosso, R; Vassallo, C | 1 |
| Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
| Aneiros-Fernandez, J; Arias-Santiago, S; Husein-ElAhmed, H; Naranjo-Sintes, R | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; McIntyre, S; Papadopoulos, NE; Rohlfs, M; Warneke, CL | 1 |
| Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF | 1 |
| Bhagwandas, K; Kamath, S | 1 |
| Berneburg, M; Eigentler, TK; Garbe, C; Ikenberg, K; Keim, U; Leiter, U; Pflugfelder, A; Weide, B | 1 |
| Li, J; Liu, C; Liu, F; Liu, J; Qu, X; Wang, Q; Yang, Z; Zhang, C; Zhao, L; Zhu, L | 1 |
| Bröcker, EB; Klink, T; Meyer, KM; Ugurel, S | 1 |
| Amatruda, T; Behrens, R; Fitch, TR; Jaslowski, AJ; Kottschade, LA; Markovic, SN; Mattar, BI; McWilliams, RR; Nikcevich, DA; Suman, VJ | 1 |
| Chen, Y; Fang, X; Hao, J; Sha, X; Shi, Y; Zhang, W | 1 |
| Bordeaux, JS; Honda, KS; Robinson, MR | 1 |
| An, X; He, Y; Li, Y; Wang, F; Wang, Z; Xu, R; Zhou, N | 1 |
| Jiang, PY; Kantorowitz, D; Yanke, R | 1 |
| Antonescu, C; Bertucci, F; Blay, JY; Bui, B; Chevreau, C; Cioffi, A; D'Adamo, DR; Delcambre, C; Isambert, N; Italiano, A; Kalbacher, E; Keohan, ML; Levra, MG; Maki, RG; Penel, N | 1 |
| Carson, WE; Chen, D; Cheverton, P; Fruehauf, JP; Kim, KB; Linette, GP; Markovic, SN; McDermott, DF; Nguyen, H; O'Day, SJ; Peterson, AC; Sosman, JA; Weber, JS | 1 |
| Celia, C; Cilurzo, F; Fresta, M; Paolino, D; Trapasso, E | 1 |
| Ahn, NG; Dallaglio, K; Ellis, LZ; Fujita, M; Gonzalez, R; Lewis, KD; Liu, W; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Spritz, RA; Takeda, M | 1 |
| Leppla, SH; Liu, S; McKenzie, AT; Wein, AN; Zhang, Y | 1 |
| Kim, KB | 1 |
| Amatruda, TT; Cohen, PA; Geoffroy, FJ; Gross, HM; Jaslowski, AJ; Kaur, JS; Kosel, ML; Kottschade, LA; Markovic, SN; McWilliams, RR; Perez, DG; Suman, VJ | 1 |
| Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y | 1 |
| Beckhove, P; Kato, M; Michels, T; Sevko, A; Shurin, GV; Shurin, MR; Umansky, L; Umansky, V; Vrohlings, M | 1 |
| Bahcall, S; Chiarion-Sileni, V; Collichio, F; Eggermont, AM; Friedlander, P; Garbe, C; Grob, JJ; Guo, W; Hauschild, A; Kefford, R; Lufkin, J; Mackiewicz, J; Mortier, L; O'Day, SJ; Robert, C; Schachter, J; Testori, A; Ugurel, S; Vukovic, V | 1 |
| Choi, S; Han, M; Hashino, S; Hosokawa, M; Kawamura, K; Kobayashi, M; Kondoh, T; Takano, M; Tanaka, J; Wang, J | 1 |
| Ideguchi, K; Ikeda, Y; Mori, T; Nakagawa, K; Okamoto, K; Sakata, K; Yasumitsu, T | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Boldt, S; Kolch, W; Weidle, UH | 1 |
| Angioli, R; Cutillo, G; Manci, N; Palaia, I; Panici, PB | 1 |
| Kunstfeld, R; Michaelis, U; Naujoks, K; Petzelbauer, P; Teifel, M; Umek, W; Wickenhauser, G; Wolff, K | 1 |
| Fukushima, M; Ono, Y; Sawada, M | 1 |
| Altmeyer, P; Ardabili, M; Gambichler, T; Hoffmann, K; Rotterdam, S; Stücker, M | 1 |
| Aydiner, A; Camlica, H; Kurul, S; Tas, F; Topuz, E | 1 |
| Bower, M; Gazzard, BG; Gotch, F; Hewitt, P; Mandalia, S; Nelson, M; Patterson, S; Portsmouth, S; Powles, T; Stebbing, J; Thirlwell, C; Wildfire, A | 1 |
| Ernstoff, MS; Fisher, J; Lewis, LD; Tretter, CP; Waugh, MG | 1 |
| Dezube, BJ; Pantanowitz, L; Pinkus, GS; Tahan, SR | 1 |
| Bedikian, AY; Ellerhorst, J; Eton, O; Papadopoulos, N; Plager, C; Smith, T | 1 |
| Daniel, FJ; Davis, ID; Jefford, M; Kiffer, JD; Somers, G | 1 |
| Brandwijk, RJ; Dings, RP; Griffioen, AW; Thijssen, VL | 1 |
| Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG | 1 |
| Sawamura, D; Shimizu, S; Tsuchiya, K; Yasui, C; Yasukawa, K | 1 |
| Fujiwara, Y; Iwasaki, H; Kaneko, M; Lee, S; Nishizawa, S; Osugi, H; Takemura, M; Tanaka, Y | 1 |
| Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H | 1 |
| Paredes-Suarez, C; Pestoni, C; Peteiro, C; Toribio, J | 1 |
| Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH | 1 |
| Hattori, H; Hayashi, T; Ishihara, M; Ishizuka, T; Kikuchi, M; Maehara, T; Matsui, T; Nakamura, S; Obara, K; Ozeki, Y; Saito, Y; Takase, B; Yura, H | 1 |
| Gross, C; Krüger, U; Rompel, R; Scholz, S | 1 |
| Becker, S; Brix, G; Dellian, M; Eichhorn, ME; Griebel, J; Jauch, KW; Michaelis, U; Ruhstorfer, H; Sauer, B; Strieth, S; Teifel, M; Werner, A | 1 |
| Barceló, R; Gil-Negrete, A; López-Vivanco, G; Muñoz, A; Rubio, I; Viteri, A | 1 |
| Bandobashi, K; Kodama, H; Miyoshi, I; Ohtsuki, Y; Saito, T; Taguchi, H | 1 |
| Bachelez, H; Dandurand, M; Descamps, V; Fardet, L; Kerob, D; Lebbe, C; Meunier, L; Morel, P; Stoebner, PE | 1 |
| Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
| Kim, IS; Kim, JH; Kim, K; Kim, YS; Kwon, IC; Lee, DS; Park, RW; Shim, WS | 1 |
| Karakuzu, A; Koc, M; Ozdemir, S | 1 |
| Adim, SB; Ali, R; Baskan, EB; Kiyici, M; Tunali, S | 1 |
| Aristu, J; Garrán, C; González Cao, M; Martín Algarra, S; Nieto, Y; Ponz, M; Viteri, S | 1 |
| Sakamoto, J; Sekine, T | 1 |
| Asensi, M; Benlloch, M; Brown, BD; Carretero, J; Estrela, JM; Mena, S; Obrador, E; Ortega, A; Petschen, I | 1 |
| Bralet, MP; Chebib, A; Gholam, D; Hauteville, D; Jasmin, C | 1 |
| Kato, N; Osawa, R; Yamane, N; Yanagi, T | 1 |
| Chu, CY; Hsiao, CH; Lee, HC | 1 |
| Tuma, RS | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 1 |
| Aikins, JK; King, SA; Menzin, AW; Mikuta, JJ; Rubin, SC | 1 |
| Bedikian, AY; Burris, HA; Buzaid, AC; Eckardt, JR; Eton, O; Jenkins, J; Legha, SS; Smetzer, L; Von Hoff, DD; Weiss, GR | 1 |
| Banerjee, S; Brown, DL; Fallis, AG | 1 |
| Bernard, S; Brouwer, KL; Gonzalez, P; Lawrence, P; Letrent, SP; Mudd, PN; Radomski, KM; Socinski, MA; Steagall, A | 1 |
| Scadden, DT; Wu, CJ | 1 |
| Orel, NF | 1 |
| Distelmans, W; Storme, G | 1 |
| Hunter, NR; Mason, KA; Milas, L; Schimming, R | 1 |
| Bresnahan, J; Brown, MA; Cabriales, S; Espina, BM; Gill, PS; Gustafson, NF; Ilaw, M; Louie, S; Orcutt, C; Scadden, DT; Tulpule, A; Winograd, B | 1 |
| Casper, ES; Fata, F; Ilson, D; Kelsen, DP; Leffel, D; O'Reilly, E; Pfister, D; Schwartz, GK | 1 |
| Berd, D; Mastrangelo, MJ; Nathan, FE; Sato, T | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA | 1 |
| Constantinides, PP; Kessler, D; Lalji, S; Lambert, KJ; Ma, W; Quay, SC; Schneider, B; Tustian, AK; Wentzel, B; Worah, D | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Amaya, H; Aotake, T; Chiba, Y; Fujii, H; Horiuchi, T; Shimomatsuya, T; Uchinami, M; Yokomachi, J | 1 |
| Beijnen, JH; Koopman, FJ; Mandjes, IA; Meerum Terwogt, JM; Rocchetti, M; Rosing, H; Schellens, JH; Schot, M; ten Bokkel Huinink, WW; Zurlo, MG | 1 |
| Dainer, PM; El Sobky, RA; Jillella, AP; Kallab, AM; Lesher, JL | 1 |
| Hamazoe, R; Komuro, I; Murata, Y; Shimoyama, M; Sumi, KI | 1 |
| Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
| Kaneko, M; Oguchi, S; Saida, T; Uhara, H | 1 |
| Feun, LG; Hurley, J; Marini, A; Savaraj, N | 1 |
| Celik, I; Engin, H | 1 |
14 review(s) available for paclitaxel and Cancer of Skin
| Article | Year |
|---|---|
Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Carboplatin; Female; Gynecologic Surgical Procedures; Humans; Liposomes; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Sister Mary Joseph's Nodule; Skin Neoplasms; Tomography, X-Ray Computed; Umbilicus | 2022 |
Management of Cutaneous Angiosarcoma: an Update Review.
Topics: Chemoradiotherapy; Hemangiosarcoma; Humans; Neoadjuvant Therapy; Paclitaxel; Skin Neoplasms | 2022 |
Advanced Acral Melanoma Therapies: Current Status and Future Directions.
Topics: Albumins; Angiogenesis Inhibitors; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interferons; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Tumor Microenvironment | 2022 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
First sonographic description of idiopathic Cutaneous Angiosarcoma of the Head and Neck.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biopsy; Dermatitis, Allergic Contact; Diagnosis, Differential; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Paclitaxel; Skin Neoplasms; Ultrasonography, Doppler, Color | 2017 |
Scalp metastasis from endometrial carcinoma: a case report and literature review.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Endometrioid; Consolidation Chemotherapy; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Head and Neck Neoplasms; Humans; Hysterectomy; Liver Neoplasms; Middle Aged; Obesity; Paclitaxel; Salpingo-oophorectomy; Scalp; Skin Neoplasms | 2018 |
Composite hemangioendothelioma and its classification as a low-grade malignancy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biopsy; Child; Drug Administration Schedule; Female; Hemangioendothelioma; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Grading; Neoplasms, Complex and Mixed; Paclitaxel; Predictive Value of Tests; Skin Neoplasms; Terminology as Topic; Treatment Outcome; Young Adult | 2013 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Immunotherapy; Ipilimumab; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Adenocarcinoma With Breast/Adnexal and Upper Gastrointestinal Differentiation Arising in an Ovarian Mature Cystic Teratoma: A Case Report and Review of the Literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Female; Gastrointestinal Neoplasms; Humans; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Skin Neoplasms; Teratoma; Treatment Outcome | 2016 |
Nab-paclitaxel in patients with metastatic melanoma.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Skin Neoplasms | 2015 |
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Logistic Models; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Remission Induction; Sex Factors; Skin Neoplasms; Treatment Outcome; Vinblastine | 2011 |
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Topics: Albumins; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Skin Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2013 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
50 trial(s) available for paclitaxel and Cancer of Skin
| Article | Year |
|---|---|
Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.
Topics: Breast Neoplasms; Female; Humans; Paclitaxel; Progression-Free Survival; Skin Neoplasms; Treatment Outcome | 2022 |
Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides | 2021 |
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B-Lymphocytes; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Insulin-Like Growth Factor I; Lymphocytes, Tumor-Infiltrating; Melanoma; Paclitaxel; Pilot Projects; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, Fibroblast Growth Factor, Type 3; Skin Neoplasms; Tumor Microenvironment | 2017 |
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Paclitaxel; Sirolimus; Skin Neoplasms; Treatment Outcome | 2013 |
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Skin Neoplasms; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2014 |
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate | 2014 |
A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Docetaxel; ErbB Receptors; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Pyridones; Pyrimidinones; Skin Neoplasms | 2015 |
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2015 |
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2015 |
Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult | 2015 |
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult | 2015 |
An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Drug Administration Schedule; Female; Humans; Indazoles; Infusions, Intravenous; Male; Melanoma; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides; Treatment Outcome; Up-Regulation | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease-Free Survival; Female; Health Status; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Skin Neoplasms; Temozolomide; Young Adult | 2016 |
Targeting Both Tumor and Stroma Cells to Treat Melanoma: NIPAWILMA.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Skin Neoplasms; Stromal Cells; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Aged; Aged, 80 and over; Albumins; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Humans; Imiquimod; Lymphocytes, Tumor-Infiltrating; Middle Aged; Monocytes; Paclitaxel; Programmed Cell Death 1 Receptor; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2017 |
Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
Topics: Adult; Aged; Cancer Vaccines; Carboplatin; Dendritic Cells; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Peptide Fragments; Pilot Projects; Skin Neoplasms | 2017 |
Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Prospective Studies; Skin Neoplasms; Treatment Outcome | 2008 |
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Scalp; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Treatment Outcome | 2008 |
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome | 2009 |
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Exanthema; Fatigue; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Pain; Skin Neoplasms; Survival Rate; Tumor Burden | 2009 |
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms | 2010 |
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cytokines; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Pyrazoles; Skin Neoplasms; Sulfonamides | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Small Cell Lung Carcinoma; Temozolomide | 2011 |
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms | 2011 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Skin Neoplasms; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2011 |
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2012 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2013 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome | 2013 |
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
Topics: Antineoplastic Agents, Phytogenic; Disease-Free Survival; Double-Blind Method; Humans; Hydrazines; L-Lactate Dehydrogenase; Melanoma; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2013 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Disease Progression; Female; Fibroblast Growth Factor 2; Humans; Interleukin-6; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms; Time Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2003 |
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Choroid Neoplasms; Disease Progression; Female; Humans; Injections, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Isoenzymes; Laminin; Lung; Male; Melanoma; Membrane Proteins; Neovascularization, Pathologic; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteoglycans; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Cells, Cultured; Umbilical Veins | 2005 |
Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Docetaxel; Female; HIV Seronegativity; Humans; Male; Middle Aged; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms; Taxoids | 2006 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Taxoids | 1995 |
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Time Factors | 1998 |
Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Edema; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Sarcoma, Kaposi; Skin Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face.
Topics: Aged; Antineoplastic Agents, Phytogenic; Facial Neoplasms; Female; Hemangiosarcoma; Humans; Male; Middle Aged; Paclitaxel; Scalp; Skin Neoplasms | 1999 |
Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Mucous Membrane; Paclitaxel; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2000 |
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Topics: Adult; Aged; Anemia; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Methacrylates; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Polymers; Prodrugs; Remission Induction; Skin Neoplasms; Solubility; Taxoids | 2001 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nervous System Diseases; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2002 |
130 other study(ies) available for paclitaxel and Cancer of Skin
| Article | Year |
|---|---|
Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab-resistant acral and mucosal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Melanoma; Nivolumab; Paclitaxel; Skin Neoplasms | 2022 |
Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: A single-institution retrospective study of 21 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hemangiosarcoma; Humans; Paclitaxel; Prospective Studies; Retrospective Studies; Skin Neoplasms | 2022 |
ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Phosphatidylserines; Skin Neoplasms; Tumor Microenvironment | 2022 |
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.
Topics: Cisplatin; Dacarbazine; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Prognosis; RNA, Long Noncoding; RNA, Messenger; Skin Neoplasms; Tumor Microenvironment | 2022 |
Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
Topics: Antineoplastic Agents; Betulinic Acid; Cell Line; Docetaxel; Humans; In Vitro Techniques; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Pentacyclic Triterpenes; Skin Neoplasms; Taxoids | 2022 |
Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Sarcoma, Kaposi; Skin Neoplasms | 2023 |
Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; East Asian People; Female; Hemangiosarcoma; Humans; Paclitaxel; Retrospective Studies; Skin Neoplasms; Taxoids | 2023 |
Radical Resection of Locally Advanced Chest Wall cSCC With Muscle Flap Reconstruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Humans; Muscles; Paclitaxel; Skin Neoplasms; Thoracic Wall | 2023 |
Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hemangiosarcoma; Humans; Paclitaxel; Skin Neoplasms; Taxoids | 2023 |
Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ipilimumab; Melanoma; Nivolumab; Paclitaxel; Skin Neoplasms; Syndrome | 2023 |
Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Radiotherapy; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2020 |
[Efficacy of combined paclitaxel/cetuximab in cutaneous squamous-cell carcinoma: A retrospective analysis of 14 patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2020 |
Cutaneous angiosarcoma: Efficacy and treatment regimen of paclitaxel maintenance therapy.
Topics: Antineoplastic Agents, Phytogenic; Hemangiosarcoma; Humans; Paclitaxel; Skin Neoplasms | 2020 |
Combined nab-paclitaxel and irradiation for large cutaneous angiosarcoma of the face and scalp with pulmonary metastases.
Topics: Aged; Albumins; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Scalp; Skin Neoplasms | 2020 |
Paclitaxel skin delivery by micelles-embedded Carbopol 940 hydrogel for local therapy of melanoma.
Topics: Acrylic Resins; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Humans; Hydrogels; Micelles; Paclitaxel; Polyethylene Glycols; Skin Neoplasms; Spectroscopy, Fourier Transform Infrared | 2020 |
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Male; Middle Aged; Paclitaxel; Prognosis; Pyrimidines; Research Design; Salvage Therapy; Skin Neoplasms; Sulfonamides; Young Adult | 2020 |
Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
Topics: Aged; CD8-Positive T-Lymphocytes; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Melanoma; Middle Aged; Myeloid-Derived Suppressor Cells; Paclitaxel; Pilot Projects; Skin Neoplasms; Tumor Microenvironment | 2021 |
The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium.
Topics: Academic Medical Centers; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Doxorubicin; Female; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Prognosis; Progression-Free Survival; Retrospective Studies; Risk Factors; Skin Neoplasms; Young Adult | 2021 |
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Indazoles; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Pyrimidines; Retrospective Studies; Skin Neoplasms; Sulfonamides; Survival Rate | 2021 |
Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Melanoma; Metformin; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms | 2021 |
Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Humans; Immune Checkpoint Inhibitors; Melanoma; Paclitaxel; Retrospective Studies; Skin Neoplasms | 2022 |
Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Administration Schedule; Epirubicin; Genital Neoplasms, Male; Groin; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Paclitaxel; Paget Disease, Extramammary; Scrotum; Skin Neoplasms; Treatment Outcome | 2017 |
Precise ratiometric loading of PTX and DOX based on redox-sensitive mixed micelles for cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Survival; Doxorubicin; Drug Carriers; Drug Compounding; Drug Therapy, Combination; Humans; Injections, Intravenous; Male; Melanoma, Experimental; Mice; Micelles; Oxidation-Reduction; Paclitaxel; Polyethylene Glycols; Skin Neoplasms | 2017 |
Metastatic Microcystic Adnexal Carcinoma with DNA Sequencing Results and Response to Systemic Antineoplastic Chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p18; Humans; Male; Mutation; Neoplasm Metastasis; Paclitaxel; Positron Emission Tomography Computed Tomography; Radiotherapy, Adjuvant; Sequence Analysis, DNA; Skin Neoplasms; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.
Topics: Animals; Antibodies; Cell Line, Tumor; Cytokines; Female; Ganciclovir; Immunologic Surveillance; Killer Cells, Natural; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Paclitaxel; Reoviridae; Skin Neoplasms; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2017 |
Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Synergism; Female; Immunotherapy; Interleukin-2; Melanoma, Experimental; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Skin Neoplasms | 2018 |
[Angiosarcoma in primary lymphoedema: A rare complication].
Topics: Aged; Antineoplastic Agents, Phytogenic; Chronic Disease; Fatal Outcome; Female; Hemangiosarcoma; Humans; Lower Extremity; Lymphedema; Paclitaxel; Skin Neoplasms | 2018 |
Angiosarcoma-related pneumohemothorax treated with intrapleural paclitaxel administration and pleurodesis with OK-432.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Hemangiosarcoma; Hemothorax; Humans; Male; Paclitaxel; Picibanil; Pleural Neoplasms; Pleurodesis; Pneumothorax; Recurrence; Skin Neoplasms | 2018 |
Enhanced Transdermal Drug Delivery by Transfersome-Embedded Oligopeptide Hydrogel for Topical Chemotherapy of Melanoma.
Topics: Administration, Topical; Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell-Penetrating Peptides; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hydrogels; Melanoma; Mice; Mice, Nude; Oligopeptides; Paclitaxel; Skin Neoplasms | 2018 |
A Case Report of Recurrent Metastatic Sebaceous Carcinoma Which Showed Favorable Response Tt Non-Fluorouracil Based Chemotherapy.
Topics: Adenocarcinoma, Sebaceous; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Positron Emission Tomography Computed Tomography; Sebaceous Gland Neoplasms; Skin Neoplasms; Treatment Outcome | 2018 |
Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms | 2018 |
Effectiveness of weekly paclitaxel for edema and pain in classic Kaposi sarcoma with widespread eruption in the lower legs.
Topics: Aged; Cancer Pain; Drug Administration Schedule; Edema; Female; Foot; Herpesvirus 8, Human; Humans; Paclitaxel; Sarcoma, Kaposi; Skin; Skin Neoplasms; Treatment Outcome | 2019 |
Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cell Line, Tumor; Female; Galactosylceramides; Immune Tolerance; Lung Neoplasms; Melanoma, Experimental; Mice; Paclitaxel; Skin Neoplasms; T-Lymphocytes, Cytotoxic | 2019 |
In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Hypersensitivity; Female; Glycerol; Ionic Liquids; Melanoma; Mice, Inbred C57BL; Paclitaxel; Skin Neoplasms | 2019 |
Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Salvage Therapy; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Cutaneous versus non-cutaneous angiosarcoma: clinicopathologic features and treatment outcomes in 60 patients at a single Asian cancer centre.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Male; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Scalp; Singapore; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2013 |
Unresectable angiosarcoma treated with bevacizumab and paclitaxel.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Paclitaxel; Remission Induction; Scalp; Skin Neoplasms | 2014 |
Cutaneous angiosarcoma clinically presenting as progressive solid facial edema in a 43-year-old male.
Topics: Adult; Antineoplastic Agents, Phytogenic; Edema; Facial Neoplasms; Hemangiosarcoma; Humans; Lung Neoplasms; Male; Paclitaxel; Skin Neoplasms; Spinal Neoplasms; Thoracic Vertebrae | 2013 |
Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Skin Neoplasms; Treatment Failure | 2013 |
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carboplatin; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Melanoma; Molecular Targeted Therapy; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Skin Neoplasms; Spheroids, Cellular; Tumor Stem Cell Assay | 2014 |
Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Female; Fluorouracil; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Mice; Mice, Nude; Nanomedicine; Neoplasm Transplantation; Paclitaxel; Polyethylene Glycols; Skin Neoplasms; Vitamin E | 2014 |
Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome | 2014 |
Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Surgical Wound Dehiscence; Thoracic Wall | 2015 |
Nanoparticle albumin-bound paclitaxel can be useful agent to advanced primary mucinous carcinoma of the skin.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antineoplastic Agents, Phytogenic; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Scalp; Skin Neoplasms | 2015 |
Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Arginine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chickens; Clarithromycin; Cyclosporine; Cytochrome P-450 CYP3A Inhibitors; Drug Compounding; Gastrointestinal Tract; Hypromellose Derivatives; Ileum; Melanoma, Experimental; Mice; Nanoparticles; Paclitaxel; Particle Size; Rats, Sprague-Dawley; Skin Neoplasms; Surface Properties; Tumor Burden | 2014 |
Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents, Phytogenic; Biomimetic Materials; Cell Line, Tumor; Cell Survival; Drug Carriers; Female; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Lung; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanospheres; Paclitaxel; Phosphatidylethanolamines; Pulmonary Surfactants; Skin Neoplasms; Vasodilation | 2014 |
Augmented EPR effect by photo-triggered tumor vascular treatment improved therapeutic efficacy of liposomal paclitaxel in mice bearing tumors with low permeable vasculature.
Topics: Animals; Antineoplastic Agents, Phytogenic; Capillary Permeability; Cell Line, Tumor; Light; Liposomes; Melanoma, Experimental; Mice, Inbred BALB C; Mice, Inbred C57BL; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols; Protoporphyrins; Skin Neoplasms; Tumor Burden | 2015 |
Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Hemangiosarcoma; Humans; Oxonic Acid; Paclitaxel; Skin Neoplasms; Taxoids; Tegafur | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Humans; Hydrogen Peroxide; Melanoma; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Temozolomide | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Managed Care Programs; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib | 2015 |
Metastatic extramammary Paget's disease responding to weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Paget Disease, Extramammary; Perineum; Skin Neoplasms | 2015 |
Optimization, in vitro cytotoxicity and penetration capability of deformable nanovesicles of paclitaxel for dermal chemotherapy in Kaposi sarcoma.
Topics: Animals; Drug Carriers; Humans; Nanostructures; Paclitaxel; Rats; Sarcoma, Kaposi; Skin Neoplasms | 2016 |
Is chemotherapy still an option in the treatment of melanoma?
Topics: Albumins; Dacarbazine; Female; Humans; Male; Melanoma; Paclitaxel; Skin Neoplasms | 2015 |
Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Face; Hemangiosarcoma; Humans; Male; Middle Aged; Paclitaxel; Propranolol; Scalp; Skin Neoplasms; Treatment Outcome | 2015 |
[The Combination Therapy of Gemcitabine Plus Paclitaxel Induced Complete Response in a Tongue Skin Brain Metastasis of Bladder Carcinoma: A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Skin Neoplasms; Tongue Neoplasms; Urinary Bladder Neoplasms | 2015 |
Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Penile Neoplasms; Radiography; Skin Neoplasms; Treatment Outcome | 2016 |
Topical delivery of paclitaxel for treatment of skin cancer.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Drug Carriers; Drug Stability; Female; Gels; Lipids; Male; Mice; Nanoparticles; Paclitaxel; Particle Size; Permeability; Skin Absorption; Skin Neoplasms | 2016 |
Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Hydrogen-Ion Concentration; Imidazoles; Liposomes; Melanoma, Experimental; Mice; Nanoparticles; Paclitaxel; Phosphatidylethanolamines; Proto-Oncogene Proteins c-bcl-2; Pyrones; RNA, Small Interfering; Skin Neoplasms; Tumor Burden | 2016 |
Translocation of BBAP from the cytoplasm to the nucleus reduces the metastatic ability of vemurafenib-resistant SKMEL28 cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Sulfonamides; Ubiquitin-Protein Ligases; Vemurafenib | 2017 |
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Facial Neoplasms; Female; Hemangiosarcoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Scalp; Skin Neoplasms; Soft Tissue Neoplasms; Young Adult | 2008 |
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Neoplasms, Second Primary; Paclitaxel; Receptor, ErbB-2; Remission Induction; Skin Neoplasms; Survival Rate; Trastuzumab | 2008 |
Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Skin Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2008 |
Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Follow-Up Studies; Hemangiosarcoma; Humans; Immunohistochemistry; Laryngeal Neoplasms; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2009 |
[Recurrence of skin and lymph nodes from asynchronous breast cancer successfully treated with paclitaxel and toremifene therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Toremifene; Ultrasonography | 2008 |
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Delivery Systems; Female; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Protein Kinases; Signal Transduction; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Acute gout during treatment with paclitaxel for metastatic melanoma.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Gout; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms | 2009 |
Perforating cutaneous metastasis from an ovarian adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Rupture, Spontaneous; Skin Neoplasms | 2010 |
Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Genital Neoplasms, Male; Humans; Male; Paclitaxel; Paget Disease, Extramammary; Skin; Skin Neoplasms; Trastuzumab | 2009 |
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib; Treatment Outcome | 2010 |
Stewart-Treves syndrome: questionable response to weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymphangiosarcoma; Paclitaxel; Skin Neoplasms; Tomography, X-Ray Computed | 2010 |
Sporotrichoid metastases to the skin from cutaneous squamous cell carcinoma in an immunocompetent patient.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arm; Carcinoma, Squamous Cell; Cisplatin; Fatal Outcome; Fluorouracil; Hand; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Paclitaxel; Radiotherapy; Skin Neoplasms | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Neprilysin; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Sister Mary Joseph's Nodule; Skin Neoplasms; Treatment Outcome; Umbilicus; Vimentin; WT1 Proteins | 2010 |
A case of epithelioid angiosarcoma of the scalp treated with paclitaxel and radiotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Follow-Up Studies; Hemangiosarcoma; Humans; Inflammation; Lymecycline; Male; Paclitaxel; Scalp; Skin Neoplasms | 2011 |
Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chitosan; Doxorubicin; Drug Carriers; Drug Delivery Systems; Female; Hydrogels; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Polyethylene Glycols; Rheology; Skin Neoplasms; Survival Rate; Time Factors | 2011 |
Regression of paclitaxel-induced maculopathy with oral acetazolamide.
Topics: Acetazolamide; Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbonic Anhydrase Inhibitors; Female; Humans; Lymphatic Metastasis; Macular Edema; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Tomography, Optical Coherence; Vision Disorders; Visual Acuity | 2012 |
The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calorimetry, Differential Scanning; Lung Neoplasms; Melanoma, Experimental; Mice; Micelles; Microscopy, Electron, Scanning; Paclitaxel; Poloxamer; Skin Neoplasms; Spectroscopy, Fourier Transform Infrared; Tissue Distribution | 2011 |
Angiosarcoma in an obese woman with worsening lymphedema after weight-loss and skin-reduction surgeries.
Topics: Dermatologic Surgical Procedures; Disease Progression; Fatal Outcome; Female; Gastric Bypass; Hemangiosarcoma; Humans; Lower Extremity; Lymphedema; Middle Aged; Obesity, Morbid; Paclitaxel; Plastic Surgery Procedures; Skin Neoplasms; Weight Loss | 2011 |
A novel effective therapy for refractory angiosarcoma of the face and scalp.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Face; Female; Gemcitabine; Hemangiosarcoma; Humans; Methotrexate; Paclitaxel; Radiotherapy; Salvage Therapy; Scalp; Skin Neoplasms | 2011 |
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Male; Paclitaxel; Prognosis; Retrospective Studies; Skin Neoplasms | 2012 |
Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses.
Topics: Administration, Cutaneous; Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Delivery Systems; Humans; Keratosis, Actinic; Paclitaxel; Skin Absorption; Skin Neoplasms; Tissue Distribution | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coloring Agents; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Interleukin-8; Melanoma; Mice; Mice, Nude; Paclitaxel; Side-Population Cells; Skin Neoplasms; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Topics: Animals; Antigens, Bacterial; Antineoplastic Agents, Phytogenic; Bacterial Toxins; Cell Line, Tumor; Cell Survival; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Skin Neoplasms; Tumor Burden; Urokinase-Type Plasminogen Activator | 2013 |
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calgranulin B; Chronic Disease; Dose-Response Relationship, Immunologic; Humans; Immunosuppression Therapy; Inflammation; Melanoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinases; Myeloid Cells; Paclitaxel; Primary Cell Culture; Skin Neoplasms; Spleen; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2013 |
MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells.
Topics: Adaptor Proteins, Signal Transducing; Antigens, Differentiation; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Cells; Cell Communication; Granuloma; Humans; Monocytes; Myeloid Differentiation Factor 88; Paclitaxel; Receptors, Immunologic; RNA, Messenger; Signal Transduction; Skin Neoplasms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
[A case of multiple skin metastases from gastric cancer successfully treated with docetaxel combined with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Floxuridine; Gastrectomy; Humans; Male; Paclitaxel; Skin Neoplasms; Splenectomy; Stomach Neoplasms; Taxoids | 2002 |
The role of MAPK pathways in the action of chemotherapeutic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Ceramides; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Flavonoids; HeLa Cells; Humans; Imidazoles; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Paclitaxel; Pyridines; Skin Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Skin relapse from cervical cancer.
Topics: Carcinoma, Squamous Cell; Female; Humans; Lymphangitis; Middle Aged; Paclitaxel; Skin Neoplasms; Uterine Cervical Neoplasms | 2002 |
Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capsules; Cations; Cell Division; Endothelium, Vascular; Humans; Liposomes; Melanoma, Experimental; Mice; Mice, SCID; Mitotic Index; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 2003 |
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids | 2003 |
Metastatic cutaneous squamous cell carcinoma arising from a previous area of chronic hypertrophic lichen planus.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chronic Disease; Cisplatin; Groin; Humans; Leg; Lichen Planus; Lymphatic Metastasis; Male; Paclitaxel; Skin Neoplasms | 2003 |
Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity.
Topics: Antibodies, Bispecific; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Interactions; ErbB Receptors; Paclitaxel; Receptors, IgG; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 2003 |
Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Dermatitis; Diagnosis, Differential; Humans; Immunoenzyme Techniques; Immunophenotyping; Male; Middle Aged; Paclitaxel; Pigmentation Disorders; Purpura; Remission Induction; Sarcoma, Kaposi; Skin Neoplasms; Tetracyclines | 2004 |
Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Cisplatin; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Skin Neoplasms; Time Factors | 2004 |
Angiogenesis gene expression profiling in xenograft models to study cellular interactions.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Base Sequence; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Molecular Sequence Data; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin Neoplasms; Transplantation, Heterologous | 2004 |
Cutaneous adenocarcinoma metastases associated with swelling of the neck and cheeks.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cheek; Head and Neck Neoplasms; Humans; Male; Neck; Neoplasms, Unknown Primary; Paclitaxel; Skin Neoplasms | 2004 |
[A case of recurrent gastric cancer with skin and lung metastasis treated by low-dose paclitaxel therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrectomy; Humans; Lung Neoplasms; Male; Paclitaxel; Skin Neoplasms; Stomach Neoplasms | 2004 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Invasiveness; Nitriles; Paclitaxel; Skin Neoplasms; Sternum; Triazoles | 2005 |
Early detection of cutaneous angiosarcoma of the face and scalp and treatment with placitaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Facial Neoplasms; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Paclitaxel; Scalp; Skin Neoplasms | 2005 |
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; HIV Infections; HIV-1; Humans; Lamivudine; Leg; Male; Nevirapine; Paclitaxel; Palatal Neoplasms; Sarcoma, Kaposi; Skin Neoplasms; Stavudine | 2005 |
Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Diffusion; Drug Carriers; Drug Stability; Endothelial Cells; Hydrogels; Injections, Subcutaneous; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Photochemistry; Skin Neoplasms | 2005 |
[Erosive verrucous skin lesion on the umbilicus of a 83 year old woman].
Topics: Adnexa Uteri; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Hysterectomy; Immunohistochemistry; Lymph Node Excision; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Skin; Skin Neoplasms; Time Factors; Umbilicus | 2005 |
Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Capsules; Contrast Media; Cricetinae; Gadolinium DTPA; Lipids; Magnetic Resonance Imaging; Melanoma; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 2006 |
Paclitaxel for progressive basal cell carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Basal Cell; Eyelid Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Skin Neoplasms | 2006 |
Papuloerythematous rash due to intralymphatic cutaneous metastasis of cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Head and Neck Neoplasms; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Lymphatic Metastasis; Lymphedema; Male; Middle Aged; Paclitaxel; Prednisolone; Respiratory Insufficiency; Skin; Skin Neoplasms; Thyroid Neoplasms | 2006 |
pH- and temperature-sensitive, injectable, biodegradable block copolymer hydrogels as carriers for paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Delayed-Action Preparations; Drug Carriers; Hydrogels; Hydrogen-Ion Concentration; In Situ Nick-End Labeling; Injections, Subcutaneous; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Polymers; Skin Neoplasms; Temperature | 2007 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Radical; Megestrol Acetate; Middle Aged; Paclitaxel; Palliative Care; Skin Neoplasms | 2006 |
Treatment of advanced classic Kaposi's sarcoma with weekly low-dose paclitaxel therapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Sarcoma, Kaposi; Skin Neoplasms; Treatment Outcome | 2006 |
Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Paclitaxel; Remission Induction; Skin Neoplasms | 2007 |
[Pulmonary pleomorphic carcinoma with rapid and peculiar metastases; report of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Cisplatin; Combined Modality Therapy; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Muscle Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pneumonectomy; Skin Neoplasms | 2007 |
Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease.
Topics: Animals; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Glutamine; Glutathione; Melanoma, Experimental; Mice; Neoplasm Metastasis; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Treatment Outcome; Tumor Necrosis Factor-alpha; X-Rays | 2007 |
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negativ
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cetuximab; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2007 |
Clearance of recurrent, classical Kaposi's sarcoma using multiple paclitaxel treatments.
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Sarcoma, Kaposi; Skin Neoplasms | 2007 |
Carcinoma erysipeloides from ovarian clear-cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Female; Gynecologic Surgical Procedures; Humans; Lower Extremity; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Skin Neoplasms | 2007 |
Reactive oxygen species may have antitumor activity in metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Hydrazines; Melanoma; Paclitaxel; Randomized Controlled Trials as Topic; Reactive Oxygen Species; Research Design; Skin Neoplasms | 2008 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
Taxol (paclitaxel) was approved by FDA for the treatment of patients with recurrent ovarian cancer.
Topics: Adenocarcinoma; Aged; Female; Humans; Paclitaxel; Salvage Therapy; Skin Neoplasms; Uterine Cervical Neoplasms | 1994 |
Differential effects of taxol on two human cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescent Antibody Technique, Indirect; HT29 Cells; Humans; Melanoma; Microtubules; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 1997 |
Posttransplant Kaposi's sarcoma treated with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Heart Transplantation; Humans; Immunocompromised Host; Male; Middle Aged; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms | 1998 |
The effect of pretreatment with docetaxel (taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors.
Topics: Animals; Chemotherapy, Adjuvant; Docetaxel; Female; Injections, Intravenous; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Skin Neoplasms; Taxoids | 1999 |
[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillaries; Carcinoma, Squamous Cell; Docetaxel; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 1999 |
Complete regression of choroidal metastases from breast cancer after docetaxel-based systemic chemotherapy.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Taxoids; Treatment Outcome | 2000 |
Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Emulsions; Female; Filtration; Humans; Melanoma; Mice; Mice, Inbred Strains; Paclitaxel; Particle Size; Serum Albumin; Skin Neoplasms; Solubility; Sterilization; Survival Analysis; Vitamin E | 2000 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
[A case of head metastases of breast cancer successfully treated with radiation therapy and docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Mastectomy, Radical; Meningeal Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Skin Neoplasms; Skull Neoplasms; Taxoids | 2000 |
Successful treatment of an intractable case of hereditary basal cell carcinoma syndrome with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Basal Cell Nevus Syndrome; Humans; Male; Middle Aged; Neck; Paclitaxel; Recurrence; Scalp; Skin Neoplasms | 2001 |
Docetaxel induced cardiotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Ventricular Dysfunction, Left | 2001 |
Docetaxel induced durable response in advanced extramammary Paget's disease: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Paclitaxel; Paget Disease, Extramammary; Radiography; Scrotum; Skin Neoplasms; Taxoids; Vincristine | 2002 |
Treatment of classical Kaposi's sarcoma with visceral involvement by weekly paclitaxel.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms | 2002 |